

Biodiversity Policy

Aragen is a leading Contract Research Organization (CRO) / Contract Development Manufacturing Organization (CDMO), servicing the global life sciences and allied industries such as pharmaceuticals, bio-pharma, animal health, agrochemical industries. Our service offerings include integrated drug discovery across small and large molecules, chemicals development, formulations, analytical development and contract manufacturing.

Aragen recognizes that conserving biodiversity is the responsibility of every organization in the long-term interest of the society, community and every other stakeholders. We are committed to adopting a systematic approach to biodiversity principles in line with provisions of the Convention on Biological Diversity (CBD, 1992) wherever it is applicable in our operations. We will implement the policy by adopting the following actions;

- Maintain legal compliance to biodiversity-related laws and regulations
- Assess risks to biodiversity and associated ecosystem from existing and planned activities and take necessary mitigation steps to minimize its impact
- Implement the mitigation hierarchy by avoiding, minimizing, restoring and if necessary, offsetting residual impacts on biodiversity
- Avoid operating in critical habitats and ecologically sensitive areas
- Avoid the introduction of any new potentially invasive, non-native species and seek to eliminate these within our operational sites
- Enhancing awareness on biodiversity within the organization
- Encourage our suppliers to manage biodiversity aspects in their operations actively

This policy will be communicated within Aragen, made available to the relevant interested parties, periodically reviewed, and updated, as necessary.

Date: 14th February 2023


Manni Kantipudi
Director & CEO